Sorrento Therapeutics Inc (SRNE)

OTC Markets
Currency in USD
0.0022
+0.0001(+4.76%)
Closed·
SRNE Scorecard
Full Analysis
Stock generally trades with high price volatility
SRNE is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.00130.0098
52 wk Range
0.00010.0210
Key Statistics
Edit
Prev. Close
0.0021
Open
0.0013
Day's Range
0.0013-0.0098
52 wk Range
0.0001-0.021
Volume
130.22K
Average Volume (3m)
91.28K
1-Year Change
-76.84%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SRNE Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Sorrento Therapeutics Inc News & Analysis

Show more

Sorrento Therapeutics Inc Company Profile

Sorrento Therapeutics, Inc., a clinical and commercial stage biopharmaceutical company, develops a portfolio of next-generation treatments for three therapeutic areas: cancer, infectious disease,and pain. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis pain treatment; and ZTlido, a lidocaine topical system for the treatment of post-herpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California. On February 13, 2023, Sorrento Therapeutics, Inc., along with its affiliate, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas. The plan was later approved as Chapter 11 liquidation on November 30, 2023.

Compare SRNE to Peers and Sector

Metrics to compare
SRNE
Peers
Sector
Relationship
P/E Ratio
0.0x−4.0x−0.5x
PEG Ratio
0.000.000.00
Price/Book
0.0x2.7x2.6x
Price / LTM Sales
0.0x8.5x3.0x
Upside (Analyst Target)
0.0%177.8%52.4%
Fair Value Upside
Unlock9.8%8.7%Unlock

Earnings

Latest Release
May 30, 2025
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

People Also Watch

4.910
SCLX
+2.51%
1.300
VERI
-7.80%
5.960
FCEL
-1.97%

FAQ

What Is the Sorrento Therapeutics Inc (SRNE) Share Price Today?

The live Sorrento Therapeutics Inc share price today is 0.00.

What Stock Exchange Does Sorrento Therapeutics Inc (SRNE) Trade On?

Sorrento Therapeutics Inc is listed and trades on the OTC Markets stock exchange.

What Is the Ticker (Stock Symbol) for Sorrento Therapeutics Inc?

The stock symbol (also called a 'ticker') for Sorrento Therapeutics Inc is "SRNE."

What Is the Current Sorrento Therapeutics Inc Market Cap?

As of today, Sorrento Therapeutics Inc market capitalisation is 1.20M.

What Is Sorrento Therapeutics Inc's (SRNE) Earnings Per Share (TTM)?

The Sorrento Therapeutics Inc EPS -1.08 (Trailing Twelve Months).

When Is the Next Sorrento Therapeutics Inc Earnings Date?

Sorrento Therapeutics Inc's next earnings report will be released on 18 Aug 2025.

Is SRNE a Buy or Sell From a Technical Analyst Perspective?

Based on today's Sorrento Therapeutics Inc moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Sorrento Therapeutics Inc Stock Split?

Sorrento Therapeutics Inc has split 1 times. (See the SRNE stock split history page for full effective split date and price information.)

How Many Employees Does Sorrento Therapeutics Inc Have?

Sorrento Therapeutics Inc currently has 949 employees.

What is the current trading status of Sorrento Therapeutics Inc (SRNE)?

As of 22 Jun 2025, Sorrento Therapeutics Inc (SRNE) is trading at a price of 0.00, with a previous close of 0.00. The stock has fluctuated within a day range of 0.00 to 0.01, while its 52-week range spans from 0.00 to 0.02.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.